|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Therapy Trials |
Dana-Farber Cancer Institute (S.K., R.X., B.L., J.B., P.Y.W), Brigham and Women's Hospital (G.D.S., S.K., P.Y.W.), Boston, MA 02115; and Massachusetts General Hospital, Brain Tumor Center (S.K., T.T.B., A.M.O., F.H.H.), Boston, MA 02114; USA
3 Address correspondence to Patrick Y. Wen, Center for Neuro-Oncology, Dana-Farber Cancer Institute and Division of Neuro-oncology, Department of Neurology, Brigham and Women's Hospital, SW430D, 44 Binney Street, Boston, MA 02115, USA (pwen{at}partners.org).
The Response Evaluation Criteria in Solid Tumors, or RECIST criteria (one-dimensional [1D] measurement), are widely used to measure response in tumors, but there are few studies evaluating these criteria in brain tumors. We compared linear and volumetric measurements in adult high-grade supratentorial enhancing gliomas to determine the agreement between measurements, in defining responses and in their subsequent relation to survival. We hypothesized that the 1D RECIST criteria maybe suitable for response assessment in adult high-grade gliomas. Tumor size on MRI scans in 104 patients with high-grade enhancing gliomas treated on clinical trial protocols was measured by using 1D (greatest length), 2D (two-dimensional: product of the two longest perpendicular diameters), 3D (three dimensional: product of the longest perpendicular diameters in one plane and the longest orthogonal diameter to that plane), enhancing volume (EV), and total volume (TV). A total of 388 T1 postgadolinium MRI scans (104 baseline and 284 follow-up scans) were evaluated. Volumetric analysis (EV and TV) was performed with commercially available software. Intraobserver and interobserver correlations (
) were high for all modalities ( > 0.92 and > 0.71, respectively). Correlation was excellent ( > 0.9) among all modalities except for 3D ( < 0.6). Patient response rates ranged from 12% to 26%. Median progression-free survival (mPFS) and six-month progression-free survival (6mPFS) were not significantly different among the methods (range, 5.3 months to 5.9 months and 42% to 48%, respectively). Landmark analyses of response at two months using linear methods predicted overall survival with hazard ratios of 0.19 to 0.29 (P < 0.005). These results suggest high concordance among 1D, 2D, TV, and EV, but not 3D, methods in assessing enhancing tumor progression and in estimating mPFS and 6mPFS in adult brain tumor patients. The tumor response at two months assessed by linear methods correlated better with overall survival. Thus, linear methods are comparable to volumetric methods, but simpler to implement for routine clinical use and for designing clinical trials of brain tumors.
Key Words: malignant glioma • tumor response • RECIST • magnetic resonance imaging
This article has been cited by other articles:
|
|
 |
|
  J.W. Henson, S. Ulmer, and G.J. Harris Brain Tumor Imaging in Clinical Trials AJNR Am. J. Neuroradiol., March 1, 2008; 29(3): 419 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. U. Lin and E. P. Winer Brain Metastases: The HER2 Paradigm Clin. Cancer Res., March 15, 2007; 13(6): 1648 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hormigo, B. Gu, S. Karimi, E. Riedel, K. S. Panageas, M. A. Edgar, M. K. Tanwar, J. S. Rao, M. Fleisher, L. M. DeAngelis, et al. YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas. Clin. Cancer Res., October 1, 2006; 12(19): 5698 - 5704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Schwartz, J. A. C. Colville, M. S. Ginsberg, L. Wang, M. Mazumdar, J. Kalaigian, H. Hricak, D. Ilson, and G. K. Schwartz Measuring tumor response and shape change on CT: esophageal cancer as a paradigm Ann. Onc., June 1, 2006; 17(6): 1018 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
